Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0426980 (
motor symptom
)
471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Multiple system atrophy (MSA), an atypical parkinsonism of alpha-synucleinopathies, has no specific biomarker of diagnosis. According to different combinations of symptoms, MSA can be classified as parkinsonism-type MSA (MSA-P) and cerebellar-type MSA (MSA-C; Watanabe et al., 2018). Amide proton transfer (APT) imaging is by far the most studied chemical exchange saturation transfer imaging for its sensitivity to mobile protons and peptides in tissues. We hypothesize that APT imaging may be a feasible biomarker of MSA-P. Twenty MSA-P patients and 20 age-matched normal controls were enrolled in this study and underwent MR exams on a 3.0-T MR scanner. Magnetization transfer spectra at 3.5 ppm were acquired at two transverse slices of the head, including the midbrain and the basal ganglia. Mann-Whitney
U
test was used to compare the asymmetrical magnetization transfer ratio (
MTR
asym
) difference between MSA-P patients and normal controls. The APT
MTR
asym
values of MSA patients in the red nucleus (RN) (SN;
P
= 0.000), substantia nigra (
P
= 0.000), thalamus (
P
= 0.000), and putamen (
P
= 0.013) were significantly higher than those in normal controls. There was a negative correlation between APT
MTR
asym
and the score of part III of the Unified Parkinson Disease Rating Scale (
R
= -0.338,
P
= 0.044) in the putamen, while there was a positive correlation between the APT
MTR
asym
and the rate of
motor symptom
progression (
R
= 0.406,
P
= 0.017) in the RN. These findings suggest that APT
MTR
asym
changes are found and may be of value in the diagnosis of MSA-P.
...
PMID:Changes of Amide Proton Transfer Imaging in Multiple System Atrophy Parkinsonism Type. 3319 64
